Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat

BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in patients with non-dialysis-dependent (NDD) CKD evaluated disease state...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Tanaka-Amino, Keiko, Otsuka, Tetsuro, Yamaguchi, Yusuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385792/
https://www.ncbi.nlm.nih.gov/pubmed/35462610
http://dx.doi.org/10.1007/s10157-022-02225-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385792/
https://www.ncbi.nlm.nih.gov/pubmed/35462610
http://dx.doi.org/10.1007/s10157-022-02225-w

Ejemplares similares